Johnson & Johnson (JNJ.N)

JNJ.N on New York Stock Exchange

101.15USD
1:30am IST
Change (% chg)

$0.02 (+0.02%)
Prev Close
$101.13
Open
$101.00
Day's High
$101.68
Day's Low
$100.81
Volume
1,469,728
Avg. Vol
2,469,597
52-wk High
$109.49
52-wk Low
$95.10

JNJ.N

Chart for JNJ.N

About

Johnson & Johnson is engaged in the research and development, manufacture and sale of a broad range of products in the health care field. The business of Johnson & Johnson is conducted by more than 275 operating companies across the world. The Company’s primary focus has been on products related to human health and well-being.... (more)

Overall

Beta: 0.52
Market Cap(Mil.): $280,438.09
Shares Outstanding(Mil.): 2,773.04
Dividend: 0.75
Yield (%): 2.97

Financials

  JNJ.N Industry Sector
P/E (TTM): 18.10 35.92 38.01
EPS (TTM): 5.59 -- --
ROI: 14.86 16.11 15.44
ROE: 22.04 16.90 16.48
Search Stocks

FBI probing what J&J knew about uterine surgery device: WSJ

- The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported.

28 May 2015

FBI probing what J&J knew about uterine surgery device - WSJ

- The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported.

28 May 2015

UPDATE 1-FBI probing what J&J knew about uterine surgery device - WSJ

May 27 - The Federal Bureau of Investigation is probing a surgical tool found to spread uterine cancer and what Johnson & Johnson knew about its risks before withdrawing its version of the device last year, the Wall Street Journal reported.

28 May 2015

J&J to submit at least 10 new drugs for approval by 2019

- U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

21 May 2015

J&J to submit at least 10 new drugs for approval by 2019

- U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

21 May 2015

UPDATE 2-J&J to submit at least 10 new drugs for approval by 2019

May 20 - U.S. healthcare conglomerate Johnson & Johnson said on Wednesday it expects to submit more than 10 new medicines with annual revenue potential of at least $1 billion each to regulators by 2019, and is testing dozens of new uses for existing medicines.

21 May 2015

CORRECTED-UPDATE 1-Achillion partners with J&J to develop hep C drugs (May 19)

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

20 May 2015

Achillion partners with J&J to develop hepatitis C drugs

- Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

20 May 2015

UPDATE 1-Achillion partners with J&J to develop hep C drugs

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

20 May 2015

Achillion partners with J&J to develop hep C drugs

May 19 - Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market one or more of its hepatitis C drugs.

20 May 2015

Earnings vs. Estimates

Search Stocks